A detailed mechanistic understanding of hyperlipidemia on CYP and UGT levels would facilitate our understanding of therapeutic outcome following hyperlipidemia-related NAFLD. Here, SLC35A2 is linked to metabolic dysfunction-associated steatotic liver disease.